Loading…

Penumbra, Inc.PENCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of devices for treating stroke, pulmonary embolism and other vascular conditions via mechanical thrombectomy (clot removal).

Momentum neutral 55
Mkt cap
$12.6B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$124M
20-day average traded
Fwd P/E
55.7×
forward earnings
ROIC−WACC
+4.8 pp
WACC 8.5%
Hurdle
+11 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$320.60
1D+0.5%
1W-0.3%
1M-1.1%
3M-1.0%
6M-2.1%
YTD+3.1%
1Y+15.1%
ATR %0.8%
Beta0.20
52w lowhigh11.5% off high

What Penumbra does

Maker of devices for treating stroke, pulmonary embolism and other vascular conditions via mechanical thrombectomy (clot removal).

Sells single-use devices, used once per procedure, direct to hospitals through its own sales force, with clinicians trained on its aspiration systems, so revenue repeats as procedure volumes grow. Neurovascular and peripheral vascular are its two product groups, and the US is the largest market.

Products and services

  • Neurovascular (stroke thrombectomy)
  • Peripheral vascular (thrombectomy, embolization)

Customers

  • Interventional neurologists/radiologists
  • Vascular surgeons
  • Hospitals

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Neurovascular and peripheral vascular…

What could go right

  • Stroke/PE thrombectomy procedure volume growth
  • International market expansion

What could go wrong

  • Competitive intensity from larger medtech players
  • Reimbursement/coding risk

Moat: narrow (IP / patents, switching costs, brand). Strong clinician relationships and proprietary aspiration-thrombectomy technology in a growing niche.

Headquarters: Alameda, California, USA · Founded: 2004 · Employees: 4,700

Named competitors

Penumbra at a glance

Size Penumbra (PEN) is a United States Health Care company (Medical Specialties) with a market value of $12.6B, the 674th largest of 3,085 United States companies the cockpit tracks. Shares closed at $320.60 on 18 Nov 2026.

Performance Over six months the shares fell 2.1%, against +25.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 17.0% over the last twelve months (peer median +5.0%); the operating margin is 12.1% (peer median 16.4%).

Valuation It trades at 55.7× forward earnings against a peer median of 19.8× (3rd most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.8 points above its cost of capital (8.5% WACC).

Short interest Short interest is 6.1% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 124PEN 98
Six months, rebased to 100: Penumbra against the median of its 20 peers (local-currency closes).

Penumbra financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.56B$1.40B$1.19B$1.06B$847M
Revenue growth—+17%+13%+25%—
Gross profit$1.04B$922M$750M$673M$526M
EBITDA$209M$210M$113M$122M$33.7M
Net income$157M$178M$14.0M$91.0M-$2.00M
Free cash flow$200M$175M$147M$82.1M-$75.0M
Capital expenditure$60.8M$63.7M$21.2M$15.2M$19.3M
Total debt$209M$220M$223M$234M$236M

Quarterly statements and history in the cockpit →

Penumbra competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%SN7733BAXBIMLENSKARTGKOSALGNCOO688271AVTRDEMANTQGENBIOPODDBRKRCOLO-BRVTYGMEDZBH7701PEN6-month return →1-month return →
Up and to the right = strong over both horizons. Penumbra is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×SN7733BAXBIMLENSKARTGKOS688271AVTRDEMANTQGENBIOPODDBRKRGMEDPENRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Penumbra is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SN7733BAXBIMLENSKARTCOOAVTRDEMANTQGENBIOPODDBRKRCOLO-BRVTYGMEDPENGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Penumbra is the large dot.

Penumbra competitors and peer comparison

Head to head with its named competitors (PEN vs SYK vs MDT vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Penumbra PEN$12.6B-2%+17%12%55.7×30.7%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%

How Penumbra compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Penumbra against its 20 peers (data as of 18 Nov 2026)
MeasurePENPeer medianRank in peer set
1-month return-1.1%+5.0%6th lowest of 21
6-month return-2.1%+25.3%3rd lowest of 21
Distance from 52-week high-11.5%-13.5%9th highest of 21
Revenue growth (TTM)+17.0%+5.0%5th highest of 21
Operating margin12.1%16.4%8th lowest of 21
Forward P/E55.7×19.8×3rd most expensive of 21
Growth the price implies (Req g, 7 yrs)30.7%10.0%2nd most demanding of 19
Growth delivered (Del g)+20.2%+7.0%4th highest of 19
Hurdle (Req g minus delivered)+10.6 pp+3.7 pp7th most demanding of 19
ROIC minus cost of capital+4.8 pp+0.9 pp6th highest of 21
EV / EBITDA58.1×12.3×2nd most expensive of 19
Net debt / EBITDA-2.2×1.4×least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%

Questions

Who are Penumbra's main competitors?
Named competitors: Stryker (Neurovascular) (SYK), Medtronic (MDT), Johnson & Johnson (Cerenovus) (JNJ), Inari Medical (private or unlisted). The cockpit's measured peer set (industry) also includes Smith & Nephew (SN..L), Olympus (7733.T), Baxter International (BAX), bioMerieux (BIM.PA), Lenskart Solutions (LENSKART.NS), Glaukos (GKOS).
Is Penumbra expensive compared with its peers?
On forward p/e it trades at 55.7× against a peer median of 19.8×, 3rd most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Penumbra stock performed?
Over six months to 18 Nov 2026 the shares returned -2.1% against +25.3% for the median peer; over one year +15.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.